Calidi Biotherapeutics (NYSEAMERICAN:CLDI – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($1.47) EPS for the quarter, FiscalAI reports.
Calidi Biotherapeutics Trading Down 5.1%
NYSEAMERICAN:CLDI traded down $0.03 on Friday, reaching $0.62. 27,622 shares of the stock traded hands, compared to its average volume of 46,353. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.24. Calidi Biotherapeutics has a 1-year low of $0.62 and a 1-year high of $24.80. The company’s 50 day moving average is $0.94 and its 200-day moving average is $3.78. The firm has a market capitalization of $1.65 million, a price-to-earnings ratio of -0.01 and a beta of 1.37.
Calidi Biotherapeutics Company Profile
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company developing cell-based therapies designed to improve the treatment of cancer. The company’s approach uses allogeneic, or donor-derived, stem cells as delivery and support systems for therapeutic agents, with the goal of protecting and enhancing the activity of immune and other anti-cancer cells within tumors. Calidi’s technology platforms include its SuperNova and NeuroNova programs. These platforms are intended to support the development of “off-the-shelf” cell therapies for solid tumors and other difficult-to-treat cancers.
Read More
- Five stocks we like better than Calidi Biotherapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
